Newcastle disease virus: A promising vector for viral therapy, immune therapy, and gene therapy of cancer

Methods in Molecular Biology

Volumn 542, Issue , 2009, Pages 565-605

  Schirrmacher, Volker ^a   Fournier, Philippe ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Immune modulation; oncolysis; tumor selectivity; tumor vaccine

Indexed keywords

AVES; AVULAVIRUS; NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE;

CANCER VACCINE;

GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; NEWCASTLE DISEASE PARAMYXOVIRUS; REVIEW;

CANCER VACCINES; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEWCASTLE DISEASE VIRUS;

EID: 67650340774     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-561-9_30     Document Type: Review

References (167)

1. Aghi M. and Martzua R.L.2005) Oncolyticviral therapies-the clinical experience Oncogene 24 : 7802-7815
2. Chlichlia K. , Schirrmacher V. and Sandaltzopoulos R.2005) Cancer immunotherapy: battling tumors with gene vaccines Curr. Med. Chem. Anti-inflammatory Anti-allergy Agents 4 : 353-365
3. Schirrmacher V.2005) T cell mediated immunotherapy of Metastases: State of the art in (2005) Expert Opin. Biol. Ther. 4 (8) : 1051-1068
4. Sinkovics J. and Horvatz J.1993) New developments in the virus therapy of cancer: historical review Intervirology 36 : 193-214
5. Asada T.1974) Treatment of human cancer with mumps virus Cancer 34 (6) : 1907-1928
6. Shimizu Y. , Hasumi K. , Okudaira Y. , Yamanishi K. and Takahashi M.1988) Immunotherapy of adVanced gynecologic cancer patients utilizing mumps virus Cancer Detect. Prev. 12 : 487-495
7. Csatary L.K. , Eckhard S. , Bukosza I. , Czegledi F. , Fenyvesi C. , Gergely P. , Bodey B. and Csatary C.M.1993) Attenuated veterinary virus vaccine for the treatment of cancer Cancer Detect. Prev. 17 : 6 19-627
8. Reichard M.W. , Lorence , R.M. and Cascino C.J.1992) Newcastle disease virus selectively kills human tumor cells J. Surg. Res. 52 : 448-453
9. Sinkovics J.G.1991) Viral oncolysates as human cancer vaccines Int. Rev. Immunol 7 : 259-287
10. Schirrmacher V. , Ahlert I. , Heicappell R. , Appelhans B. and Von Hoegen P.1986) Successful application of non-oncogenic viruses for antimetastatic cancer immunotherapy Cancer Rev. 5 : 19-49
11. Heicappell R. , Schirrmacher V. , von Hoegen P. , Ahlert T. and Appelhans B.1986) Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I: parameters for optimal therapeutic effects Int. J. Cancer 37 : 569-577
12. Lorence , R.M. , Reichard K.W. , Katubig B.B. , Reyes H.M. , Phuangsab H. , Mitchell B. R. , Cascino J. , Walter R.J. and Peeples M.E.1994) Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy J. Ntl Cancer Inst.Bethesda) 86 : 1228-1233
13. Umansky V. , Shatrov V.A. , Lehmann V. and Schirrmacher V.1996) Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B Int. Immunol. 8 (4) : 491-498
14. Cassel W.A. and Murray D.R.1992) A tenyear follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate Med. Oncol. Tumor Pharmacother. 9 (4) : 169-71
15. Russell S.J.2002) RNA viruses as virotherapy agents Cancer Gene Ther 9 : 961-966
16. Stoidl D.F. , Lichty B. , Knowles S. , Marius R. , Atkins H. , Sonenberg N. and Bell J.2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus Nature Med. 6 (7) : 821-825
17. Kasuya H. , Takeda S. , Shimoyama S. , Shikano T. , Nomura N. , Kanazumi N. , Nomoto S. , Sugimoto H. and Nakao A.2007) Oncolytic virus therapy-foreword Curr Cancer DrugTargets 7 (2) : 123-125
18. Alexander D.J.1997) Newcastle disease and other Paramyxoviridae infections In: Diseases of Poultry ( Calnek , B.W. , Barnes H.J. , Beard C.W. , McDougald L. and Saif J.Y.M. eds.), 10th ed. Lowa State University , Ames, IA , 541-569
19. Lorence R.M. , Roberts M.S. , Groene W.S. and Rabin H.2003) Replication-competent, oncolytic Newcastle disease virus for cancer therapy In: Replication-Competent Viruses for Cancer Therapy. Hernaiz Driever P. , Rabkin S.D. , eds.), Collection: Monographs in Virology Basel , Karger , vol. 22 , pp. 160 - 182
20. Alexander D.J.1988) Historical aspects In:Newcastle Disease. Alexander D.J.ed.) Kluwer , Boston , pp. 1 - 10
21. Doyle T.M.1927) A hitherto unrecorded disease of fowls due to a filter-passing virus J Comp Pathol Ther 40 : 144-169
22. De Leeuw O. and Peeters B.1999) Completenucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae J. Gen. Virol 80 (Pt 1) : 131-136
23. Lamb RA., Parks G.D.2007) Paramyxoviridae: their viruses and their replication. In Fields Virology. Fifth edition.Knipe D.M. and Howley P.M. eds). Wolters Kluwer /LippincottWilliams & Wilkins, pp. 1449-1496.
24. Wheelock E.F. , Dingle J.H.1964) Observations on the repeated administration of viruses to a patient with acute leukaemia. A preliminary report N. Engl. J. Med. 24 : 271 : 645-651
25. Cassel W.A. , Garrett R.E.1965) Newcastle Disease Virus as an antineoplastic agent Cancer 18 : 863-868
26. Csatary L.K.1971) Viruses in the treatment of cancer Lancet 2 (7728) : 825
27. Sinkovics J.G., Horvath J.C.eds) (2005) Viral therapy of cancer , Marcel Dekker, New York.
28. http://www.cancer.gov/cancertopics/pdq/ cam/NDV/HealthProfessional/
29. Sinkovics J.G. and Horvath J.C.2000) Newcastle Disease Viurs (NDV): brief history of its oncolytic strains J. Clin. Virol. 16 (1) : 1-15
30. Schirrmacher V. , Haas C. , Bonifer R. , AhlertT. , Gerhards R. and Ertel C.1999) Human tumor cell modification by virus infection: an efficient and safe way to produce cancervaccine with pleiotropic immune stimulatory properties when using Newcastle Disease Virus Gene Ther 6 : 63-73
31. Janke M. , Peeters B. , de Leeuw O. , Moorman R. , Arnold A. , Fournier P. , Schirrmacher V.2007) Recombinant Newcastle Disease Virus (NDV)with inserted gene coding for GM-CSF as new vector for cancer immunogene therapy Gene Ther 14 (23) : 1639-1649
32. DiNapoli J.M. , Kotelkin A. , Yang L. , Elankumaran S. , Murphy B.R. , Samal S.K. , Collins P.L. and Bukreyev A.2007) Newcastle Disease Virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens Proc. Natl. Acad. Sci. USA 104 (23) : 9788-9793
33. Nagai Y. , Hamaguchi M. , Toyoda T.1989) Molecular biology of Newcastle disease virus Prog Vet Microbiol Immunol 5 : 16-64
34. Yusoff K. , Tan W.S.2001) Newcastle disease virus: macromolecules and opportunities Avian Pathol 30 : 439-455
35. Calain P. , Roux L.1993) The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA J. Virol 67 (8) : 4822-4830
36. Peeters B.P. , Gruijthuijsen Y.K. , de Leeuw O.S. , Gielkens A.L.2000) Genome replication of Newcastle disease virus: involvement of the rule-of-six Arch. Virol 145 (9) : 1829-1845
37. Lamb R.A. , Paterson R.G. , Jardetzky T.S.2006) Paramyxovirus membrane fusion: lessons from the F and HN atomic structures Virology 344 (1) : 30-37
38. Suzuki Y. , Suzuki T. , Matsunaga M. , MatsumotoM..J.1985) Gangliosides as paramyxovirusreceptor. Structural requirement of sialo-oligosaccharides in receptors for hemagglutinating virus of Japan (Sendai virus) and Newcastle disease virus Biochem (Tokyo) 97 (4) : 1189-1199
39. Ferreira L. , Villar E. and Munoz-Barroso I.2004) Gangliosides and N-glycoproteins function as Newcastle Disease Virus receptors Int. J. Biochem. Cell Biol. 36 : 2344-2356
40. Villar E. and Barroso I.M.2006) Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview Glycoconj J 23 (1-2) : 5-17
41. Cantin C. , Holguera J. , Ferreira L. , Villar E. and Munoz-Barroso I.2007) Newcastle Disease Virus may enter cells by caveolae-mediated endocytosis J. Gen. Virol. 88 : 559-569
42. Laliberte J.P. , McGinnes L.W. , Peeples M.E. , Morrison T.G.2006) Integrity of membranelipid rafts is necessary for the ordered assembly and release of infectious Newcastle Disease Virus particles J. Virol. 80 (21) : 10652-10662
43. Pantua H.D. , McGinnes L.W. , Peeples M.E. , Morrison T.G.2006) Requirements for the assembly and release of Newcastle Disease Virus-like particles J. Virol 80 (22) : 11062-11075
44. Fournier P. , Zeng J. and Schirrmacher V.2003) Two ways to induce innate immune responses in human PBMCs: Paracrine stimulation of IFN- responses by viral protein or dsRNA Int. J. Oncol 23 : 673-680
45. Taniguchi T. and Takaoka A.2002) The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors Curr. Opin. Immunol 14 : 111-116
46. Sadler A.J. and Williams B.R.2007) Structure and function of the protein kinase R Curr Top Microbiol Immunol 316 : 253-292
47. Fiola C. , Peeters B. , Fournier P. , Arnold A. , Bucur M. and Schirrmacher V.2006) Tumor selective replication of Newcastle Disease Virus: association with defects of tumor cells in antiviral defence Int. J. Cancer 15 , 119 (2) : 328-338
48. Haller O. , Kochs G. and Weber F.2007) Interferon, Mx, and viral countermeasures Cytokine Growth Factor Rev 18 (5-6) : 425-433
49. Malathi K. , Dong B. , Gale M. and Silverman R.H.2007) Small self-RNA generated by RNase L amplifies antiviral innate immunity Nature 446 : 816-819
50. Ahlert T. , Schirrmacher V.1990) Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns Cancer Res 50 (18) : 5962-5968
51. Fábián U. , Csatary C. , Szeberányi J. and Csatary L.K.2007) p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle Disease Virus strain in tumor cell lines J. Virol 81 (6) : 2817-2830
52. Elankumaran S. , Rockemann D. and Samal S.K.2006) Newcastle Disease Virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death J. Virol. 80 (15) : 7522-7534
53. Liu T.C. and Kirn D.2007) Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions Cancer Res 67 (2) : 429-432
54. Apostolidis L. , Schirrmacher V. and Fournier P.2007) Host mediated anti-tumor effect of oncolytic Newcastle Disease Virus after locoregional application Int. J. Oncol 31 : 1009-1019
55. Ito Y. , Nagai Y. and Maeno K.1982) Interferon production in mouse spleen cells and mouse fibroblasts (L cells) stimulated by various strains of Newcastle disease virus J. Gen. Virol 62 (Pt 2) : 349-352
56. Lorence R.M. , Rood P.A. and Kelley K.W.1988) Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor- alpha and augmentation of its cytotoxicity J. Natl. Cancer Inst 80 (16) : 1305-1312
57. Aigner M., Janke M., Luleí M., Beckhove P., Fournier P., Schirrmacher V.2008) An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. Int. J. Oncol 32(4 ):777-789.
58. Sato K. , Hida S. , Takayanagi H. , Yokochi T. , Kayagaki N. , Takeda K. , Yagita H. , Okumura K. , Tanaka N. , Taniguchi T. and Ogasawara K.2001) Antiviral response by natural killer cells through TRAIL gene induction by IFN- / . Eur. J. Immunol 31 : 31-38
59. Schirrmacher V. , Bai L. , Umansky V. , Yu L. , Xing Y. and Qian Z.2000) Newcastle Disease Virus activates macrophages for antitumor activity Int. J. Oncol. 16 : 363-373
60. Umansky V. , Shatrov V.A. , Lehmann V. and Schirrmacher V.1996) Induction of nitric oxide synthesis in macrophages by Newcastle Disease Virus is associated with activation of nuclear factor-B Int. Immunol. , 8 (4) : 491-498
61. Washburn B. , Weigand M.A. , Grosse-Wilde A. , Janke M. , Stahl H. , Rieser E. , Sprick M.R. , Schirrmacher V. and Walczak H.2003) TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle Disease Virus J. Immun. 170 (4) : 1814-1821
62. Cella M. , Salio M. , Sakakibara Y. , Langen H. , Julkunen I. and Lanzavecchia A.1999) Maturation, activation and protection of dendritic cells induced by double-stranded RNA J. Exp. Med 189 : 821-829
63. Bai L. , Koopmann J. , Fiola C. , Fournier P. and Schirrmacher V.2002) Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients Int. J. Oncol. 21 : 685-694
64. Lodolce J.P. , Burkett P.R. , Boone D.L. , Chien M. , Ma A.2001) T cell-independent interleukin 15Ralpha signals are required for bystander proliferation J. Exp. Med. 194 (8) : 1187-1194
65. Dubsky P. , Saito H. , Leogier M. , Dantin C. , Connolly J.E. , Banchereau J. , Palucka A.K.2007) IL-15-induced human DC efficiently prime melanoma-specific naive CD8 + T cells to differentiate into CTL Eur J Immunol. 37 (6) : 1678-1690
66. Von Hoegen P. , Weber E. and Schirrmacher V.1988) Modification of tumor cells by a low dose of Newcastle Disease Virus; augmentation of the tumor-specific T cell response in the absence of an anti-viral response Eur. J. Immunology 18 : 1159-1166
67. Schild H.J. , von Hoegen P. and Schirrmacher V.1988) Modification of tumor cells by a low dose of Newcastle Disease Virus: II. Augmented tumor specific T cell response as a result of CD4 + and CD8 + immune T cell cooperation Cancer Immunol. Immunother , 28 : 22-28
68. Von Hoegen P. , Heicappell R. , Griesbach A. , Altevogt P. and Schirrmacher V.1988) Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals Proc. 8th Sapporo Cancer Seminar Invasion & Metastasis 9 : 117-133
69. Ertel C. , Millar N.S. , Emmerson P.T. , Schirrmacher V. and von Hoegen P.1993) Viral hemagglutinin augments peptide specific cytotoxic T-cell responses Eur. J. Immunol 23 : 2592-2596
70. Termeer C.C. , Schirrmacher V. , Bröcker E.B. and Becker J.C.2000) Newcastle-Disease-Virus infection induces a B7-1/ B7-2 independent T-cell-costimulatory activity in human melanoma cells Cancer Gene Ther 7 (2) : 316-323
71. Haas C. , Ertel C. , Gerhards R. and Schirrmacher V.1998) Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus Int. J. Oncol 13 : 1105-1115
72. Washburn B. and Schirrmacher V.2002) Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis Int. J. Oncol 21 (1) : 85-93
73. Takeda K. , Kaisho T. and Akira S.2003) Toll-like receptors Annu Rev Immunol 21 : 335-76
74. Thompson AJ and Locarnini SA.2007) Tolllike receptors, RIG-I-like RNA helicases and the antiviral innate immune response Immunol. Cell. Biol. 85 (6) : 435-445
75. Kato H. , Sato S. , Yoneyama M. , Yamamoto M. , Uematsu S. , Matsui K. , Tsujimura T. , Takeda K. , Fujita T. , Takeuchi O. and Akira S.2005) Cell type-specific involvement of RIG-I in antiviral response Immunity 23 (1) : 19-28
76. Melchjorsen J. , Jensen S.B. , Malmgaard L. , Rasmussen S.B. , Weber F. , Bowie A.G. , Matikainen S. , Paludan S.R.2005) Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner J. Virol 79 (20) : 12944-12951
77. Magyarics Z. , Rajnavölgyi E.2005) Professional type I interferon-producing cells-a unique subpopulation of dendritic cells Acta Microbiol Immunol Hung 52 (3-4) : 443-462
78. Kawai T. and Akira S.2005) Pathogen recognition with Toll-like receptors Curr. Opin. Immunol 17 : 338-344
79. Schulz O. , Diebold S.S. , Chen M. , Näslund T.I. , Nolte M.A. , Alexopoulou L. , Azuma Y.T. , Flavell R.A. , Liljeström P. , Reis E. and Sousa C.2005) Toll-like receptor 3 promotes cross-priming to virus-infected cells Nature 433 (7028) : 887-892
80. Lindenmann J.1974) Viruses as immunological adjuVants in cancer Biochim Biophys Acta 355 (1) : 49-75
81. Kyburz D. , Aichele P. , Speiser D.E. , Hengartner H. , Zinkernagel R.M. , Pircher H.1993) T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides Eur. J. Immunol 23 : 1956-1962
82. Sato K. , Hida S. , Takayanagi H. , Yokochi T. , Kayagaki N. , Takeda K. , Yagita H. , Okumura K. , Tanaka N. , Taniguchi T. and Ogasawara K.2001) Antiviral response by natural killer cells through TRAIL gene induction by IFNalpha/ beta Eur J Immunol 31 : 3138
83. Kumar-Sinha C. , Varambally S. , Sreekumar A. and Chinnaiyan A.M.2002) Molecular cross-talk between the TRAIL and interferon signalling pathways J. Biol. Chem 277 : 575-585
84. Washburn B. , Weigand M.A. , Grosse-Wilde A. , Janke M. , Stahl H. , Rieser E. , Sprick M.R. , Schirrmacher V. and Walczak H.2003) TRAIL mediates tumoricidal activity of human monocytes stimulated by Newcastle Disease Virus J. Immunol 170 : 1814-1821
85. Le Bon A. , Schiavoni G. , D'Agostino G. , Gresser I. , Belardelli F. and Tough D.F.2001) Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo Immunity 14 (4) : 461-470
86. Matzinger P.1994) Tolerance, danger, and the extended family Ann. Rev. Immunol 12 : 991-1045
87. Matzinger P.2002) The danger model: A renewed sense of self Science 296 : 301-305
88. Forden C.2004) Do T lymphocytes correlate danger signals to antigen? Med Hypotheses. 62 (6) : 898-906
89. Goodbourn , L. Didcock and Randall R.E.2000) Interferons: cell signa, immune modulation, antiviral response and virus countermeasures , J. Gen. Virol. 81 : 2341-2364
90. Hengel U.H. , Koszinowski U.H. and Conzelmann K.K.2005) Viruses know it all new insights into IFN networks , Trends Immunol 26 : 396-401
91. Yoneyama M. , Kikuchi M. , Natsukawa T. , Shinobu N. , Imaizumi T. , Biyagishi M , Taira K. , Akira S. and Fujita T.2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses Nat. Immunol. 5 : 730-737
92. Gitlin L. , Barchet W. , Gilfillan S. , Cella M. , Beutler B. , Flavell R.A. , Diamond M.S. and Colonna M.2006) Essential role of MDA-5 in type I IFN responses to polyriboinosinic:po lyribocytidylic acid and encephalomyocarditis picornavirus Proc. Natl. Acad. Sci. USA 103 (22) : 8459-8464
93. Hornung V. , Ellegast J. , Kim S. , Brzózka K. , Jung A. , Kato H. , Poeck H. , Akira S. , Conzelmann K.K. , Schlee M. , Endres S. and Hartmann G.2006) 5' -Triphosphate RNA is the ligand for RIG-I Science 314 (5801) : 994-997
94. Bowie A.G. and Fitzgerald K.A.2007) RIG-I: tri-ing to discriminate between self and non-self RNA Trends Immunol 28 (4) : 147-150
95. SerVant M.J. , Tenoever B. and Lin R.2002) Overlapping and distinct mechanisms regulating RF-3 and IRF-7 function J Interferon Cytokine Res 22 (1) : 49-58
96. Levy D.E. , Mariá I. , Smith E. and Prakash A.2002) Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback J. Interferon Cytokine Res 22 (1) : 87-93
97. Von Hoegen P. , Zawatzky R. and Schirrmacher V.1990) Modification of tumor cells by a low dose of Newcastle Disease Virus: III. Potentiation of tumor specific cytolytic T cell activity via induction of interferon alfa, beta Cellular Immunology 126 : 80-90
98. Rogge L. , Barberis-Maino L. , Biffi M. , Passini N. , Presky D.H. , Gubler Sinigaglia E.1997) Selective expression of an interleukin- 12 receptor component by human helper 1 cells J. Exp. Med 185 : 825
99. Zeng J., Fournier P. and Schirrmacher V.2002) Induction of interferon and tumor necrosis factor-related apoptosis-inducing blood mononuclear cells by hemagglutininneuraminidase but not F protein of Newcastle Disease Virus. Virology, 297: 19-30.
100. Zeng , J. , Fournier , P. , Schirrmacher , V (2002) Stimulation of human natural interferonresponse via paramyxo-virus hemagglutinin lectin-cell interaction J. Mol. Med. 80 : 443-451
101. Fournier P. , Zeng J. , Von der Lieth C.W. , Washburn B. , Ahlert T. and Schirrmacher V.2004) Importance of serine 200 for functional activities of the hemagglutininneuraminidase protein of Newcastle Disease Virus Int. J. Oncol 24 : 623-634
102. LeBon A. and Tough D.F.2002) Links between innate and adaptive immunity via type I interferon Curr. Opin. Immunol 14 : 432-426
103. Tough D.F.2004) Type I interferon as link between innate and adaptive immunity through dendritic cell stimulation Leuk. Lymphoma 45 (2) : 257-264
104. Gallucci S. and Matzinger P.2001) Danger signals: SOS to the immune system Curr. Opin. Immunol 13 : 114
105. Bian H. , Wilden H. , Fournier P. , Peeters B. and Schirrmacher V.2006) In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein Int. J. Oncol 29 : 1359-1369
106. Schirrmacher V., Fournier P., Newcastle Disease Virus: a promising vector for viral therapy of cancer in "Viral therapy of cancer" , Eds. Harrington KJ , Pandha HS and Vile RG, Wiley Publishers, published the 18 April 2008 (ISBN: 978-0-470-01922-1 ).
107. Lorence R.M. , Roberts M.S. , O'Neil J.D. , Groene W.S. , Miller J.A. , Mueller S.N. and Bamat M.K.2007) Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus Curr. Cancer Drug Targets 7 (2) : 157-167
108. Freeman A.I. , Zakay-Rones Z. , Gomori J.M. , Linetsky E. , Rasooly L. , Greenbaum E. , Rozenman-Yair S. , Panet A. , Libson E. , Irving C.S. , Galun E. and Siegal T.2006) Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme Mol Ther 13 (1) : 221-228
109. Pecora A.L. , Rizvi N. , Cohen G.I. , Meropol N.J. , Sterman D. , Marshall J.L. , Goldberg S. , Gorss P. , O'Neil J.D. , Groene W.S. , Roberts M.S. , Rabin H. , Bamat M.K. and LorenceM.2002) Phase I trial of intravenous administration of PV 701, an oncolytic virus, in patients with adVanced solid cancers J. Clin. Oncol. 20 (9) : 2251-2266
110. Hotte S.J. , Lorence R.M. , Hirte H.W. , Polawski S.R. , Bamat M.K. , O'Neil J.D. ,Roberts M.S. , Groene W.S. and Major P.P. (2007) An optimized clinical regimen for the oncolytic virus PV701 Clin. Cancer Res 13 (3) : 977-985
111. Laurie S.A. , Bell J.C. , Atkins H.L. , Roach J. , Bamat M.K. , O'Neil J.D. , Roberts M.S. , Groene W.S. and Lorence R.M.2006) A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization Clin. Cancer Res 12 (8) : 2555-2562
112. Czegledi A. , Wehmann E. and Lomniczi B.2003) On the origins and relationships of Newcastle disease virus vaccine strains Hertfordshire and Mukteswar, and virulent strain Herts'33 Avian Pathol 32 : 271-276
113. Csatary L.K. , Moss R.W. , Beuth J. , Töröcsik B. , Szeberenyi J. and Bakacs T.1999) Beneficial treatment of patients with adVanced cancer using a Newcastle disease virus vaccine (MTH-68/H) Anticancer Res 19 (1B) : 635-638
114. Csatary L.K. and Bakács T.1999) Use of Newcastle disease virus vaccine (MTH- 68/H) in a patient with high-grade glioblastoma JAMA 281 (17) : 1588-1589
115. Csatary L.K. , Csatary C. , Gosztonyi G. and Bodey B.2006) Promising MTH-68/H Oncolytic Newcastle Disease Virus therapy in human high grade gliomas Chapter IV In: Focus on Brain Cancer Research ( Andrew V Yang , ed.), Nova Science Publishers New York , pp. 69 - 82
116. Csatary L.K. , Eckhardt S. , Bukosza I. , Czegledi F. , Fenyvesi C. , Gergely P. , Bodey B. and Csatary C.M.1993) Attenuated veterinary virus vaccine for the treatment of cancer Cancer Detect. Prev 17 (6) : 619-627
117. Position of the Scientific council on the antitumor studies conducted in Hungary on the Newcastle Disease Virus.1998) Orv. Hetil 139 : 2903-2905.
118. Nelson N.J.1999) Scientific interest in Newcastle Disease Virus is reviving J. Natl. Cancer Inst 91 : 1708-1710
119. Miller L.T. and Yates V.J.1971) Reactions of human sera to avian adenoviruses and Newcastle disease virus Avian Dis. 15 (4) : 781-788
120. Charan S. , Mahajan V.M. and Agarwal L.P.1981) Newcastle disease virus antibodies in human sera Indian J. Med. Res 73 : 303-307
121. Van Pel A. , Van der Bruggen P. , Coulie P.G. , Brichard V.G. , Lethe B. , Van den Eynde B. , Uyttenhove C. , Renauld J.C. and Boon T.1995) Genes coding for tumor antigens recognized by cytolytic T lymphocytes Immunol. Rev. 145 : 229-250
122. BaxeVanis C.N. and Papamichail M.1994) Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy Crit. Rev. Oncol. Hematol 16 : 157-179
123. Schirrmacher V. , Ahlert T. , Pröbstle T. , Steiner H.H. , Herold-Mende C. , Gerhards R. , Hagmäller E. and Steiner H.H.1998) Immunization with virus-modified tumor cells Semin. Oncol 25 (6) : 677-696
124. Steiner H.H. , Bonsanto M.M. , Beckhove P. , Brysch M. , Schuele-Freyer R. , Geletneky K. , Kremer P. , Golamrheza R. , Bauer H. , Kunze S. , Schirrmacher V. and Herold-Mende C.2004) Anti-tumor vaccination of patients with glioblastoma multiforme: a pilot study to assess: Feasibility, safety and clinical benefit J. Clin. Oncology 22 (21) : 4272-4281
125. Gilboa E.1999) The makings of a tumorrejection antigen Immunity 11 : 263-270
126. Coulie P.G. , Lehman F. , Lethá B. , Herman J. , Lurquin C. , Andrawiss M. and Boon T.1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma Proc. Natl. Acad. Sci. USA 92 : 7976-7980
127. Lupetti R. , Pisarra P. , Verrecchia A. , Farina C. , Nicolini G. , Anichini A. , Bordignon C. , Sensi M. , Parmiani G. and Traversari C.1998) Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocytes (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage J. Exp. Med. 188 : 1005-1010
128. Schirrmacher V. and Heicappell R.1987) Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II: establishment of specific systemic anti tumor immunity Clin. Exp. Metastasis 5 : 147-156
129. Plaksin D. , Porgador A. , Vadai E. , Feldman M. , Schirrmacher V. and Eisenbach L.1994) Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV) Int. J. Cancer 59 (6) : 796-801
130. Shoham J. , Hirsch R. , Zakay-Rones Z. , Osband M.E. and Brennert H.J.1990) Augmentation of tumor cell immunogenicity by viruses-an approach to specific immunotherapy of cancer Nat Immun Cell Growth Regul 9 (3) : 165-172
131. Key M.E. and Hanna M.G. Jr.1981) Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity. II. Influence of the local inflammatory response on immune reactivity J. Natl. Cancer Inst 67 (4) : 863-869
132. Schirrmacher V.2005) Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory Cancer Immunol. Immunother 54 : 587-598
133. Schirrmacher V. , Haas C. , Bonifer R. , Ahlert T. , Gerhards R. and Ertel C.1999) Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle Disease Virus Gene Ther. 6 : 63-73
134. Schirrmacher V. , Feuerer M. , Fournier P. , Ahlert T. , Umansky V. and Beckhove P.2003) T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity Trends Mol Med 9 (12) : 526-534
135. Schirrmacher V. and von Hoegen P.1993) Importance of tumor cell membrane integrity and viability for CTL activation by cancer vaccines Vaccine Res 2 : 183-196
136. Ahlert T. , Sauerbrei W. , Bastert G. , Ruhland S. ,Bartik B. , Simiantonaki N. , Schumacher J. , Häcker B. , Schumacher M. and Schirrmacher V.1997) Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer J Clin Oncol 15 (4) : 1354-1366
137. Schirrmacher V.2005) Anti-tumor immune memory and its activation for control of residual tumor cells and improvement of patient survival In: Virus Therapy of Human Cancers ( Sinkovics , J. , Horvath , J. , eds), Marcel Decker , New York
138. Lehner B. , Schlag P. , Liebrich W. and Schirrmacher V.1990) Postoperative active specific immunization in curatively resected colorectal cancer patients with virus-modified autologous tumor cell vaccine Cancer Immunol. Immuntherap 32 : 173-178
139. Schlag P. , Manasterski M. , Gerneth Th. , Hohenberger P. , Dueck M. , Herfarth Ch. , Liebrich W. and Schirrmacher V.1992) Active specific Immunotherapy with NDV modified autologous tumor cells following liver metastases resection in colorectal cancer: First evaluation of clinical response of Phase II trial Cancer Immunol. Immunother 35 : 325-330
140. Bohle W. , Schlag P. , Liebrich W. , Hohenberger P. , Manasterski M. , Möller P. , and Schirrmacher V.1990) Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumour cell vaccine: first clinical results with tumour cell vaccines modified with live but avirulent Newcastle Disease Virus Cancer 66 : 1517-1523
141. Liebrich W. , Schlag P. , Manasterski M. , Lehner B. , Stöhr M. and Möller P. , Schirrmacher V.1991) In vitro and clinical characterization of a Newcastle Disease virus-modified autologous tumor cell vaccine for treatment of colorectal cancer patients Europ. Journal Cancer 27 : 703-710
142. Ockert D. , Schirrmacher V. , Beck N. , Stoelben E. , Ahlert T. , Flechtenmacher J. , Hagmäller E. , Nagel M. and Saeger H.D.1996) Newcastle Disease Virus infected intact autologous tumor cell vaccine for adjuVant active specific immunotherapy of resected colorectal carcinoma Clin. Cancer Res 2 : 21-28
143. Pomer S. , Schirrmacher V. , Thiele R. , Löhrke H. and Staehler G.1995) Tumor response and 4 year survival data of patients with adVanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous r-IL-2 and IFN-Alpha 2b Int. J. Oncol 6 : 947-954
144. Ahlert T. , Sauerbrei W. , Bastert G. , Ruhland S. , Bartik B. , Simiantonaki N. , Schumacher , J. , Häcker B. , Schumacher M. , and Schirrmacher V.1997) Tumor cell number and viability as quality and efficacy parameters of autologous virus modified cancer vaccines J. Clin. Oncol. 15 : 1354-1366
145. Karcher J. , Dyckhoff G. , Beckhove P. , Reisser C. , Brysch M. , Ziouta Y. , Helmke B. , Weidauer H. , Schirrmacher V. and Herold-Mende C.2004) Anti-tumor vaccination with HNSCC with autologous virus-modified tumor cells Cancer Res 64 (21) : 8057-8061
146. Haas C. , Lulei M. , Fournier P. , Arnold A. and Schirrmacher V.2005) T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine Vaccine 23 : 2439-2453
147. Haas C. , Lulei M. , Fournier P. , Arnold A. and Schirrmacher V.2005) A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable anti-tumor activity in human lymphocytes Int. J. Cancer 118 (3) : 658-667
148. Bian H. , Fournier P. , Moormann R. , Peeters B. and Schirrmacher V.2005) Selective gene transfer in vitro to tumor cells via recombinant Newcastle Disease Virus Cancer Gene Ther 12 : 295-303
149. Bian H. , Fournier P. , Moormann R. , Peeters B. and Schirrmacher V.2005) Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein Int. J. Oncol 26 : 431-439
150. Bian H. , Fournier P. , Peeters B. and Schirrmacher V.2005) Tumor-targeted gene transfer in vivo via recombinant Newcastle Disease Virus modified by a bispecific fusion protein Int. J. Oncol. 27 : 377-384
151. Conzelmann K.K.1998) Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes Ann. Rev. Genet 32 : 123-162
152. García-Sastre A.1998) Negative-strand RNA viruses: applications to biotechnology Trends Biotechnol 16 : 230-235
153. Nagai Y. and Kato A.1999) Paramyxovirus reverse genetics is coming of age Microbiol. Immunol 43 : 613-624
154. Roberts A. and Rose J.K.1998) Recovery of negative-strand RNA viruses from plasmid DNAs: a positive approach revitalizes a negative field Virology 247 : 1-6
155. Peeters B.P.H. , de Leeuw O.S. , Koch G. and Gielkens A.L.J.1999) Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is major determinant for virulence J. Virol 73 : 5001-5009
156. Römer-Oberdörfer A. , Mundt E. , Mebatsion T. , Buchholz U. and Mettenleiter T.C.1999) Generation of recombinant lentogenic Newcastle disease virus from cDNA J. Gen. Virol 80 : 2987-2995
157. Mebatsion T. , Verstegen S. , De Vaan L.T. , Römer-Oberdörfer A. and Schrier C.C.2001) A recombinant Newcastle Disease Virus with low-level V protein expression is immunogenic and lacks pathogenicity for chicken embryos J. Virol 75 : 420-428
158. Vigil A. , Park M.S. , Martinez O. , Chua M.A. , Xiao S. , Cros J.F. , Martínez-Sobrido L. , Woo S.L. and García-Sastre A.2007) Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus Cancer Res 67 (17) : 8285-8292
159. Zhao H. and Peeters B.P.2003) Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication J. Gen. Virol 84 (Pt 4) : 781-788
160. Huang Z. , Krishnamurthy S. , Panda A. and Samal S.K.2001) High-level expression of a foreign gene from the most 3' -proximal locus of a recombinant
161. Nakaya T. , Cros J. , Park M.S. , Nakaya Y. , Zheng H. , Sagrera A. , Villar E. , García- Sastre A. and Palese P.2001) Recombinant Newcastle Disease Virus as a vaccine vector J. Virol 75 : 11868-11873
162. Bureyev A. , Huang Z. , Yang L. , Elankumaran S. , St. Claire M. , Murphy B.R. , Samal S.K. and Collins P.L.2005) Recombinant Newcastle Disease Virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates J. Virol. 79 : 13275-13284
163. Ge J. , Deng G. , Wen Z. , Guobing T. , Wang Y. , Shi J. , Wang X. , Li Y. , Hu S. , Jiang Y. , Yang C. , Yu K. , Bu Z. and Chen H.2007) Newcastle Disease Virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses J. Virol 81 (1) : 150-158
164. Sivasamugham L.A. , Cardosa M.J. , Tan W.S. and Yusoff K.2006) Recombinant Newcastle Disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits J. Med. Virol 78 (8) : 1096-1104
165. Veits J. , Wiesner D. , Fuchs W. , Hoffmann B. , Granzow H. , Starick E. , Mundt E. , Schirrmeier H. , Mebatsion T. , Mettenleiter T.C. and Römer-Oberdörfer A.2006) Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza Proc. Natl. Acad. Sci. USA 103 (21) : 8197-8202
166. Huang Z. , Elankumaran S. , Yunus A.S. , Samal S.K.2004) A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV J. Virol 78 (18) : 10054-10063
167. Alexander D.J.1988) Newcastle disease virus - an avian paramyxovirus In: Newcastle Disease ( Alexander D.J. ed), Kluwer , Boston , pp. 11 - 22